Clinical Features and Natural History of Nonalcoholic Steatosis Syndromes

By Yngve Falck-Ytter1, Zobair Younossi2, Giulio Marchesini3, Arthur McCullough1. Seminars in liver disease (Print), 2001

698 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/66d3dd69b66b051684fc33c99108a06adde0b9c2

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. S. Bellentani
2. J. Clark
3. Amalia Gastaldelli
4. S. Grundy
5. E. Bugianesi
6. E. Ferrannini
7. Gerald I. Shulman

In Epidemiology

1. S. Bellentani
2. Giulio Marchesini
3. J. Clark
4. Amalia Gastaldelli
5. J. Browning
6. S. Grundy
7. E. Bugianesi
8. E. Ferrannini

In Pathology and Forensic Medicine

1. S. Bellentani
2. J. Clark
3. Amalia Gastaldelli
4. E. Bugianesi

Citations in the corpus

• Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos nutrition and liver study (2005, methodology): “8 Four hundred ninety-seven (15%) had suspected liver disease (SLD) according to at least one of the following criteria: (1) ALT # 30 U/L; (2) elevated !-glutamyltransferase (GGT) (#35 U/L); (3) presence of hepatitis B surface antigen (HBsAg); and (4) presence of antibodies against hepatitis C virus”
• Epidemiology of Non-Alcoholic Fatty Liver Disease (2010, background): “While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now k”
• Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms (2005, background): “There is growing concern regarding NAFLD due to its high prevalence in the general population and its potential for progression to cirrhosis [1], terminal liver failure [2] and hepatocellular carcinoma [3].”
• Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. (2005, background): “NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) comprises a spectrum of conditions extending from simple hepatic steatosis (fatty infiltration of the liver) to end-stage liver disease (6, 7, 15, 28, 33).”
• Updated Definitions of Healthy Ranges for Serum Alanine Aminotransferase Levels (2002, background): “Indeed, current estimates indicate that the prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the general population is 20% and 3%, respectively (29).”
• The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. (2003, neutral): “Liver biopsies show steatosis in over 75% of morbidly obese subjects (61).”
• Age-related changes in total and regional fat distribution. (2009, neutral): “Most cases of fatty liver occur between 40 and 60 years of age (Falck-Ytter et al., 2001).”
• The Epidemiology of Nonalcoholic Fatty Liver Disease in Adults (2006, background): “Based on series in GI clinics, it was originally thought that NAFLD was most common in middle-aged white women.(46,47) However, population-based studies indicate that NAFLD is probably more common in men, particularly under the age of 50 years, and in Mexican-Americans compared with non-Hispanic whi”
• Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome (2003, methodology): “The 5 components of the metabolic syndrome were available in all patients, and subjects having 3 or more of the following criteria were labeled as metabolic syndromes23: (1) fasting glucose 110 mg/dL; (2) central obesity (waist circumference 102 cm [men] and 88 cm [women]); (3) arterial pressure 130”